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Abstract
Background: To help design clinical trials of adjuvant bisphosphonate therapy for breast cancer, the temporal
incidence of bone metastasis was investigated in a cohort of patients. We have tried to draw the criteria to use
adjuvant bisphosphonate.
Methods: Consecutive breast cancer patients undergoing surgery between 1988 and 1998 (5459 patients) were
followed up regarding bone metastasis until December 2006. Patients’ characteristics at the time of surgery were
analyzed by Cox’s method, with bone metastasis as events. Patient groups were assigned according to Cox’s
analysis, and were judged either to require the adjuvant bisphosphonate or not, using the tentative criteria: high
risk (>3% person-year), medium risk (1-3%), and low risk (<1%).
Results: Bone metastasis incidence was constant between 1.0 and 2.8% per person-year more than 10 years. Non-
invasive cancer was associated with a very low incidence of bone metastasis (1/436). Multivariate Cox’s analysis
indicated important factors for bone metastasis were tumor grade (T), nodal grade (pN), and histology. Because T
and pN were important factors for bone metastasis prediction, subgroups were made by pTNM stage. Patients at
stages IIIA, IIIB and IV had an incidence of >3% per person-year, patients with stage I <1% per person-year, and
those with stages II were between 1 and 3%. Further analysis with histology in stage II patients showed that stage
IIB with high risk histology also had a high incidence (3% person year), whereas stage IIA with medium risk
histology were <1%.
Conclusions: Bone metastasis incidence remained constant for many years. Using pN, T, and histopathology,
patients could be classified into high, medium, and low risk groups.
Background
Bone metastasis is a common complication of breast
cancer, with >70% of patients having bone metastasis at
autopsy [1]. Despite this high incidence of metastasis
found post-mortem, routine bone survey in breast can-
cer patients is not considered as enough evidence to
perform [2]. Two Italian randomized clinical trials failed
to prove the usefulness of surveillance that included
bone scanning in breast cancer patients [3,4].
Recently, a new treatment involving bisphosphonates
for bone metastasis of breast cancer has been developed.
Bisphosphonates have evident place in therapy for bone
metastasis by reducing bone-related events [5-8].
Bisphosphonates should prevent the development of
bone metastasis in breast cancer [9,10]. Gnant et al [9]
reported that the administration of bisphosphonate
(zoledronic acid) significantly improved disease-free sur-
vival. In this study, the use of bisphosphonate was pri-
marily intended to assess the effect of zoledronic acid
on bone mineral density. The benefits of bisphosphonate
w e r en o tc o n f i n e dt ot h ef r e q u e n c yo fb o n em e t a s t a s i s ,
but extended to distant and loco-regional metastases in
other tissues. Bone metastasis was clearly decreased by
the addition of bisphosphonate, even though the differ-
ence did not reach significance [9]. Several ongoing
large-scale adjuvant bisphosphonate trials have end-
points dealing with disease-free survival and bone
metastasis-free survival [10]. Thus, bone-specific therapy
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For the use of adjuvant with bone-specific drugs, an
understanding of temporal incidence of bone metastasis
in a specific group of patients is very important, both in
planning clinical trials and the actual clinical practice.
Therefore, we have investigated the temporal incidence
of bone metastasis in subgroups derived from various
variables of patient, using data from an open cohort of
breast cancer patients that had undergone surgery.
Methods
Patients
This prospective study is an open cohort investigation
carried out at a single hospital from January 1988 to
December 2006, of breast cancer patients that had
undergone surgery at the Cancer Institute Hospital in
Tokyo, Japan, between January 1988 and December
1998. Patients with any of the following conditions were
excluded: (a) bilateral breast cancer in the past or at the
time of the surgery, (b) multifocal breast cancer in
the ipsilateral breast, (c) bone metastasis diagnosed at
the time of surgery or within 30 days after surgery, or
(d) patients with incomplete information available on
important prognostic factors, such as tumor size and
lymph node status. After exclusion on these criteria,
5459 patients were enrolled. The study was approved by
the Institutional Review Board and verbal informed con-
sent was obtained from the patients.
Diagnosis and follow-up
Patients received a physical check every 3 months for
first 2 years, every 6 months thereafter up to 10 years
after surgery, and subsequently once a year. Bone scans
were done to survey for metastases, initially at the time
of surgery for staging and once a year thereafter for
5 years. Subsequently, bone scans were done at 7 and
10 years. Scans were also carried out when a physician
suspected, or wanted to exclude, the possibility of bone
metastasis. When metastasis to other tissues was
detected, bone scan was performed to determine the
spread of the disease. If the bone scans were positive or
equivocal for metastasis, other imaging techniques
including X-ray, computed tomography, and magnetic
resonance imaging were used to confirm the diagnosis.
Recurrence other than in the bone was also determined
based on physical examination, chest X-ray, ultrasono-
graphy, computed tomography, magnetic resonance ima-
ging and histological examinations. Patients were
followed until December 2006.
Factors analyzed
Several patient characteristics obtained at the time of
s u r g e r yw e r eu s e dt od e t e r m i n eap o s s i b l el i n kw i t h
bone metastasis; those that could be measured by rou-
tine clinical examination are shown in Additional file 1.
All factors were converted to categorical variables, these
being age at surgery (Age), menstruation state (Mens),
breast tumor (T) with minor modification such that T2
tumors were divided into small (2.1-3.0 cm) and large
(3.1-5.0 cm), clinical and pathologic lymph node state
(N, pN, and axN), histology of breast tumor, status of
estrogen (ER) and progesterone receptors (PgR) of the
tumor, and adjuvant therapy. Tumors were classified as
in situ: non-invasive cancer, T0: no detectable tumor,
T1: ≦2.0 cm, T2 small: 2.1-3.0 cm, T2 large: 3.1-5.0 cm,
T3: ≧5.1 cm and T4: any size with direct extension to
chest wall or skin, according to the 2002 UICC-TNM
classification [11]. Histologic classification was per-
formed according to the criteria of The Japanese Breast
Cancer Society [12], which differs from the WHO classi-
fication. In the Japanese system, invasive ductal carci-
noma not otherwise specified (NOS) according to WHO
classification system is subdivided into 3 categories
based on morphology: papillotubular, solid-tubular and
scirrhous carcinomas [12,13]. Lymph node status could
be classified by 3 methods according to the 2002 UICC
criteria: N: clinical or preoperative classification, pN:
pathologic classification and axN: number of axillary
nodes involved. Because pathologic classification is more
accurate than clinical classification, pN and axN were
used for analysis. axN was classified as 1: negative, 2:
1-3 positive nodes, 3: ≧4 positive nodes. pN was taken
as a representative lymph node factor, and used for mul-
tivariate Cox’s analysis. Estrogen receptor status of a
tumor was regarded as positive when the concentration
was >13 fmol/mg cytosol protein. Progesterone receptor
status of tumor was regarded as positive when the con-
centration was >10 fmol/mg cytosol protein. Adjuvant
therapy was classified as no adjuvant, hormone therapy
(mainly tamoxifen) only, chemotherapy only, and both
hormone therapy and chemotherapy.
pTNM classifications according to the 2002 UICC cri-
teria [11] were also used for data analysis. Since patients
with bone metastasis at the time of surgery were
omitted from the study, the TpNM classifications used
were I, IIA, IIB, IIIA, IIIB, and IV (except for bone
metastasis). Because pTNM classification is the result of
combined factors, these stages were not used in Cox
analysis.
Analysis procedure and criteria for bone scan
recommendation
Data analysis was conducted as follows: first, bone
metastasis incidence was calculated in all patients, fol-
lowing which patient characteristics were analyzed to
determine those related to the incidence of bone metas-
tasis. Finally, by making subgroups according to
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metastasis incidence, the incidence rate in each sub-
group was calculated and formed the following tentative
criteria for the use of bisphosphonates as adjuvants. The
tentative criteria were as follows: patients with a bone
metastasis incidence of <1% per person-year group were
not recommended for bisphosphonate treatment;
patients with a >3% per person-year incidence group
were recommended for routine use of bisphosphonates,
and patients in the 1 - 3% per person-year incidence
group fell into an undetermined grouping in which the
use of adjuvant bisphosphonates would be performed at
the physician’s or patient’s discretion.
Statistical methods
A binominal method was used to calculate the 95% con-
fidence interval for bone metastasis percentage (StatXact
version 3.1, SPSS Inc., Chicago, IL). Kaplan-Meier’s
method was used to compare patient characteristics.
The proportionality of each hazard was confirmed by
plotting a log-minus-log curve. Cox’s proportional
hazard regression model was used to calculate the
hazard ratio or relative risk by univariate and multivari-
ate analysis. Multivariate Cox’s regression analysis was
conducted using a forward stepwise method with a like-
lihood ratio. Factors that were statistically significant in
univariate analysis were analyzed by multivariate analy-
sis. In univariate analysis, a p-value of < 0.05 was con-
sidered significant. In multivariate analysis, the inclusion
criterion was set at p.0.05 and the exclusion criterion
was set at p.0.10. Statistical data analysis, except for
those, specified ones were conducted with SPSS soft-
ware, version 11.0 (SPSS Inc.).
Results
Additional file 1 shows patient demographics and the
percentage of patients who developed bone metastasis.
The annual bone metastasis incidence was 1.0-2.8% per
person-year for the first 10 years (Figure 1). Very few
bone metastases was observed in patients with non-
invasive cancer and Paget’s disease, and hence data
from these patients were omitted from further analysis.
Bone metastasis was diagnosed in 690 patients out of
the 5023 patients with invasive breast cancer,
Additional file 2 summarizest h er e s u l t so fu n i v a r i a t e
and multivariate Cox’s proportional hazard analysis. The
relative risk was calculated for each factor, using a
hazard ratio = 1 as a baseline in each classification. In
univariate Cox’s analysis, age, tumor, nodal state (pN
and axillary N), histology, and adjuvant therapy were
characteristics that significantly correlated with an
increased incidence in bone metastasis. However, men-
struation status, ER, and PgR were not significantly cor-
related. Since both pN and axillary node are lymph
node classifications, pN was taken as a representative
value of nodal involvement in multivariate analysis. In
the multivariate Cox’s proportional hazard analysis, age,
breast tumor, pN, histology and adjuvant therapy were
significantly correlated factors. Multivariate Cox’sp r o -
portional hazard analysis gave the following results; for
pN, the hazard ratios were 2.41 in patients with pN= 1,
5.09 in patients with pN = 2, and 4.92 in patients with
pN = 3, taking the value of patients with pN = 0 as 1.0.
For tumor size, the hazard ratios were 0.62 in patients
with non-palpable tumor, 1.63 in patients with T2 small,
2.04 in patients with T2 large, 2.74 in patients with T3,
and 3.25 in patients with T4, taking the value of patients
with T1 as 1.0. For histology, the hazard ratios were
2.16 in patients with scirrhous cancer, 2.74 in patients
with invasive lobular carcinomas, and 1.49 in patients
with solid tubular carcinoma, taking the value of the
patients with papillotubular carcinoma as 1.0. Adjuvant
therapy was included in multivariate analysis as an
adjusting factor. This factor was worse (i.e. giving a high
hazard ratio: 1.05 in hormone therapy, 2.88 in che-
motherapy, and 2.07 in chemotherapy plus hormone
therapy) in univariate analysis, and better (giving a low
hazard ratio: 0.64 in hormone therapy, 0.8 in che-
motherapy, and 0.66 in chemotherapy plus hormone
therapy) in multivariate analysis. This discrepancy could
be explained as follows: the high hazard ratio in univari-
ate analysis reflected the use of adjuvant therapy for
high risk patients, and the low hazard ratio arose
because the patient imbalance was adjusted by other
factors, revealing the true effect of adjuvant therapy on
bone metastasis development, adjuvant hormone,
chemotherapy or both decreasing the risk of bone
metastasis.
Figure 2 gives the Kaplan-Meier curves of patients
grouped by pTNM stage. Patients with stage I disease
had a bone metastasis rate of less than 1% per person-
year. Bone metastasis incidence in patients with stage
IIA and IIB disease was 1 to 3% per person-year,
although stage IIA patients had a significantly lower
incidence than stage IIB patients. The incidence of bone
metastasis was >3% per person-year in patients with
stage IIIA, IIIB, or IV disease.
Further analysis was conducted on patients with stage
II having an incidence of bone metastasis of between 1
and 3% per person-year. Among the significant factors,
T, pN, and histology showed a strong correlation with
the development of bone metastasis (Additional file 2).
pTNM classification includes T and pN information.
Histology could be divided into 2 subgroups from the
hazard ratio obtained by Cox’s analysis (Additional file
2). Judging from the result of Cox’s analysis, patients
with scirrhous cancer or invasive lobular cancer were
assigned to a high risk group, and patients with
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type of cancer were assigned to a medium risk group.
Figure 3A shows the incidence of bone metastasis in
stage IIA and IIB patients with medium risk histology,
and Figure 3B the incidence in stage IIA and IIB
patients with high risk histology. The stage IIA patients
with low risk histology showed an annual incidence of
<1% per person-year, with stage IIB patients having high
risk histology showing the annual incidence at or more
than 3% per person-year. The remainders were between
1 - 3%.
Since these result seem to be complicated, we sought
a simpler classification. Because pN proved to be a very
strong factor related to bone metastasis in Cox’sa n a l y -
sis, bone metastasis incidence in patients were compared
with regard to pN status (positive vs negative). Patients
group with positive nodes exhibited an annual bone
metastasis incidence of about or >3% per person-year,
and patients group with negative nodes an incidence of
~1% (Figure 4).
The patient group with recurrence of metastasis to tis-
sues other than bone during the follow up period was
another high risk group. Figure 5 shows bone metastasis
incidence in patients with recurrence of metastasis to a
Figure 1 Annual and Cumulative Incidence of Bone Metastasis for All Breast Cancer Patients. Annual (shaded bar) and cumulative (open
bar) incidence of bone metastasis is given for all patients enrolled, including those with non-invasive breast cancer. The numbers of patients at
risk and with bone metastasis events are shown in the lower column.
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Figure 2 Bone Metastasis Free Fraction Curves of Breast
Cancer Patients According To pTNM Stage. Bone metastasis free
fractions are shown for patients with invasive breast cancer patients
according to pTNM stage. Each curve shows the bone metastasis-
free fraction of patients as follows: in situ (black square), stage I
(open circle), stage IIA (gray circle), stage IIB (black circle), stage IIIA
(open triangle), stage IIIB (black inverted triangle), and stage IV other
than bone (open square). Point marks indicate events. Oblique
straight lines indicate 3% per person-year (solid) and 1% per person-
year (dotted) lines.
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fied to this group, and 242 patients developed bone
metastasis during the follow-up period. This group had
an incidence of bone metastasis of >3% per person-year.
Based on the results of this analysis, candidates for
adjuvant bisphosphonate therapy are summarized in
Additional file 3.
Discussion
Over 70% of breast cancer patients present bone metas-
tasis at autopsy [1]. Indeed, 63% (555/880) of patients
dying of the disease had had bone metastasis detected
by scanning. In 1970’ and 1980’s, bone scan had been
considered an essential procedure during both initial
staging and regular follow-ups in patients with breast
cancer, because of the high incidence of bone metastasis
being reported [12-15]. However, a re-evaluation of the
procedure in the late 1980’s suggested the incidence of
bone metastasis was not as great as previously thought
[16-19]. The results of Rosseli et al and GIVCO [3,4]
indicated that, while periodic survey picked up recur-
rence more than just a physician’s check-up, the overall
survival rate did not differ from patients not given a
bone scan. Consequently, guidelines were issued indicat-
ing that a bone scan was not justified at regular intervals
during follow-up [2].
With the development of bisphosphonates, agents that
effectively reduce bone-related events caused by bone
metastasis, an effective treatment is now available [5-7].
Indeed, recent guidelines for breast cancer treatment
strongly recommend bisphosphonate treatment in cases
of bone metastasis [8]. These results indicate that early
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Figure 3 Bone Metastasis Free Fraction Curves of Stage II Breast Cancer Patients.B o n em e t a s t a s i sf r e ef r a c t i o n sa r es h o w nf o rs t a g eI I
breast cancer patients with medium (left) and high risk histology (right). Grey stair-like line indicates stage IIA and black stair-like line indicates
stage IIB. Oblique straight lines indicate 3% per person-year (solid) and 1% per person-year (dotted) lines.
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Figure 4 Bone Metastasis Free Fraction Curves of Invasive
Breast Cancer Patients with and without Lymph Nodal
Metastasis. Bone metastasis free fractions are shown for patients
with pathological lymph node metastasis (black step-like line) and
without (gray step-like line). Oblique straight lines indicate 3% per
person-year (solid) and 1% per person-year (dotted) lines.
Figure 5 Bone Metastasis Free Fraction Curve of Patients with
Recurrence Other Than Bone. The bone metastasis free fraction is
shown by the black step-like line. Oblique straight lines indicate 3%
per person-year (solid) and 1% per person-year (dotted) lines.
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can reduce bone-related events and improve quality of
life. Regrettably, these studies conducted by Rosseli et al
and GIVCO did not investigate bone-related events
because this concept was not extant when the two stu-
dies were conducted [9,10].
The use of bisphosphonates in preventing the develop-
ment of bone metastasis is currently under investigation,
clodronate and oral bisphosphonate both being investi-
gated as adjuvants. Three large randomized studies have
been reported [7,20,21]. Two trials [7,20] gave positive
data for the use of clodronate, but one trial [21] was
negative. Meta-analysis including these studies revealed
no significant difference in overall survival, or in bone
metastasis-free survival, in breast cancer patients receiv-
ing adjuvant clodronate treatment [22]. Recently the
results of more potent bisphosphonate adjuvant, zole-
dronic acid, were reported by Gnant et al [9], who have
reported that its administration was associated with a
significant improvement in disease-free survival. In their
study, the use of bisphosphonate was primarily intended
to assess the effect of zoledronic acid on bone mineral
density. The benefits from bisphosphonate were not
confined to the frequency of bone metastasis, but
extended to all distant and loco-regional metastases.
While bone metastasis was indeed decreased by the use
of bisphosphonate, this effect was not significantly sig-
nificant [9]. There are several ongoing large-scale adju-
vant bisphosphonate trials looking at the endpoints of
disease-free survival and bone metastasis survival [10].
This report presents the temporal incidence of bone
metastasis associated with breast cancer using data
obtained at a single hospital. Bone metastasis has been
diagnosed by several experts using consistent criteria
[23,24], and confirmatory studies were carried out by
using other imaging methods. Many follow-up bone
scan studies in breast cancer have been reported. Unfor-
tunately, most of them had limited numbers of patients,
short follow-up times, or both [16-19]. Most studies
reported their results for only a 2-year follow-up period
after surgery. However, as Figure 1 indicates, the annual
incidence of bone metastasis is constant for at least the
first 10 years following surgery. Indeed, breast cancer
patients who present recurrence after a long disease-free
interval can often be observed in daily clinical practice.
Our results are consistent with these observations and
stress the importance of long-term monitoring.
A number of prognostic factors can be used to esti-
mate survival and disease-free survival of breast cancer
patients. These include nodes status, histologic classifi-
cation of the tumor, nuclear grading of the tumor,
tumor size, estrogen and progesterone receptor status,
the S-phase fraction, mitotic index, p53, Ki-67, among
other parameters [25-28]. Of these prognostic factors,
characteristics routinely available to clinical practice
were selected for this investigation. Analysis of patient
characteristics for correlation with bone metastasis
showed that nodal status (pN), tumor size (T) and his-
tology were strongly positively correlated with an
increase in the incidence of bone metastasis. Because
very few bone metastases developed in patients with
non-invasive carcinoma and Paget’s disease, surveillance
for bone metastasis is not necessary in these patients.
Because our study started in 1988, old pathologic classi-
fication was used. A serious flaw was therefore the use
of Japanese-based pathological classification, which dif-
fers from the WHO classification on the point that inva-
sive ductal carcinoma not otherwise specified (NOS)
according to WHO classification system was subdivided
into 3 categories based on morphology, i.e. papillotubu-
lar, solid-tubular and scirrhous carcinomas [12,13].
Pathological criteria could not be used other than that
for Japan. However, other factors were able to be trans-
lated into the 2002 UICC criteria, so that the present
results can be used regardless of the pathological classi-
fication of invasive ductal cancer.
In future, the criterion of percentage (person-year) for
the use of bisphosphonates to prevent bone metastasis
should be required with regard to cost-effectiveness. A
report from Breast Cancer Research Group in Ontario,
Canada, indicates that tests with a rigid criterion in
detecting metastases in <1% of patients have a signifi-
cant false-positive rate are not clinically useful [29].
Another report indicated that bone survey should be
conducted in patient groups whose bone metastasis inci-
dence was 3% [30]. We tentatively adopted 1 to 3% cri-
terion for the adjuvant use of bisphosphonates, which
referred to patients in groups with a bone metastasis
incidence of <1% per person-year not being recom-
mended for adjuvant bisphosphonate treatment, patients
in groups with a >3% per person-year incidence being
recommended, and patients in groups with a 1 - 3% per
person-year incidence falling into an undetermined area
where it is unclear whether the prophylactic use of
bisphosphonates can provide any significant benefit.
This concept needs to be verified by actual clinical stu-
dies. Patients with stage IIA having medium risk histol-
ogy and stage I showed <1% per person-year incidence
are not recommended for adjuvant bisphosphonate ther-
apy. Patients with stage III, stage IV (except for bone),
stage IIB with high risk histology, and those with recur-
rence other than bone showing >3% per person-year
incidence, are seen as candidates that should receive
adjuvant bisphosphonate therapy. Patients with stage IIB
having medium risk histology and IIA having high risk
histology had a bone metastasis incidence between 1
and 3% per person-year. From another point of view,
patients with positive nodes had an annual bone
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patients the candidates to receive adjuvant bisphospho-
nate therapy, whereas patients with negative nodes with
an annual incidence of ~1% are not recommended the
adjuvant treatment. Our data will help improve the
design of future clinical studies.
Conclusions
This study has shown the following. 1) The incidence of
bone metastasis is relatively constant for at least 10
years after surgery, with an annual incidence rate of
between 1 and 2.8% per person-year. 2) Using tentative
criteria based on the annual bone metastasis incidence,
patients groups can be classified into those who are and
other who are not potential candidates for the adjuvant
bisphosphonate therapy. These results should provide
an impetus for the adjuvant bisphosphonates as an
important intervention in the prevention bone metasta-
sis of breast cancer patients following surgery.
Additional material
Additional file 1: Patients’ characteristics and incidence of skeletal
metastasis. Additional file 1 shows patient demographics and the
percentage of patients who developed bone metastasis.
Additional file 2: Univariate and multivariate Cox’s proportional
hazard model analysis of factors correlated with incidence of
skeletal metastasis. Additional file 2 summarizes the results of univariate
and multivariate Cox’s proportional hazard analysis.
Additional file 3: Tentative candidates for adjuvant
bisphosphonates. Additional file 3 illustrates candidates for adjuvant
bisphosphonate therapy.
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